Clinical studies on the PCSK9 inhibitor class show they dramatically lower LDL-C levels – by an average of up to 60% – when combined with other lipid lowering therapies such as statins and cholesterol absorption inhibitors.

Data from the FOURIER and ODYSSEY cardiovascular outcomes trials show PCSK9 inhibitors can lower the risk of serious CV events such as myocardial infarction, strokes, and revascularisations, as well as reducing mortality in high-risk patients.